수술 불가능한 췌장암 환자에서 방사선 치료의 역할

Role of Radiotherapy in Unresectable Pancreatic Carcinoma

From 1988 to 1991, nineteen patients with unresectable localized pancreatic carcinoma were treated with radiotherapy and/or hyperthemia or in combination with chemotherapy. Radiation dose of 4500-5000 cGy with or without additional 500-1000 cGy was administered over 5 to 6 weeks to the pancreatic tumor area using 10 MV linear accelerator. Five of 19 patients were given chemotherapy, either neoadjubant or maintenance setting with FAM regimen (5-FU, adriamycin and mitomycin C), which was repeated every 4 weeks for one wear or until progression. Symptomatic palliation was achieved in 17 among 19 patients (89%) and objetive response (complete or partial response in CT finding) was achieved in 5 among 11 patients (45%). The median survival time was 9 months and one-year survival rate, 32%. Local- regional failure was documented in 10 among 13 patients (77%) and distant failures were found in the liver (3 patients) and carcinomatosis (2 patients). Prognostic significance of various factors such as age, sex, performance status, tumor location, stage, etc. were assessed. Any factors did not have the prognostic significance in univariate analysis. Treatment was well tolerated in most of the patients with only mild to moderate toxicity.